Trump Announces Argentina-U.S. Tariff Elimination
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly.TARIFFS:The Argentine foreign ministry posted aon X to announce a reciprocal trade and investment agreement between Argentina and the United States. The U.S. will eliminate reciprocal tariffs for 1,675 Argentine products and the U.S. government also committed to a timely review of tariffs on steel and aluminum, according to the statement.DRUG DISCOUNT SITE:President Trump is expected to announce the launch of the TrumpRx website, an adviser told Axios, moving ahead with a plan to offer discounted drug prices through special agreements with drug companies, Axios' Marc Caputo. The launch will allow people to buy medications directly through the new government portal with discounts the White House has negotiated with the drug manufacturers, the author notes. The announcement is scheduled for 7pm ET. The site will offer discounts on drugs from major drug companies including Pfizer, AstraZeneca, EMD Serono, Eli Lillyand Novo Nordisk, according to the publication.Meanwhile, STAT News' Elaine Chen, John Wilkerson, and Chelsea Cirruzzothat the website is expected to display the cash prices for certain drugs and direct patients to other sites where they can buy the therapies, but some experts are skeptical the platform will meaningfully affect affordability, the report noted. Publicly traded large cap drugmakers include AstraZeneca, Bristol Myers, Eli Lilly, GSK, Johnson & Johnson, Merck, Novartis, Pfizer, Rocheand Sanofi.Pfizer has since "announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation agreement with the U.S. government enabling patients to pay lower prices for their prescription medicines, while strengthening America's role as a global leader in pharmaceutical innovation." Through the TrumpRx platform, uninsured or insured American patients who choose to self-pay outside of insurance will be offered savings that range as high as 85%, and on average 50%, for the large majority of Pfizer's primary care treatments and select specialty brands, the company said. Pfizer will also continue to expand PfizerForAll, a direct-to-consumer platform launched in 2024.CHINA ORDERS FOR BOEING:Jefferies keeps a Buy rating on Boeingwith a $295 price target saying President Trump wrote on social media about positive phone call with China President Xi ahead of his trip in April. The post directly mentions aircraft and engines, which could be a signal for China's first Boeing 737 orders since 2017, the firm tells investors in a research note. Jefferies points out that China accounted for 21% of Boeing's deliveries from 2010-2019.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 25.630
Low
24.00
Averages
28.56
High
35.00
Current: 25.630
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, and others. Its PF-08653944 is an ultra-long-acting fully biased GLP-1 receptor agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pfizer Faces Challenges Yet Remains a Long-Term Investment Opportunity
- Long History: Founded in 1849, Pfizer has survived over a century in the highly competitive pharmaceutical industry, with a corporate ethos emphasizing resilience in adversity, which instills confidence in investors.
- Stock Price Decline: Pfizer's stock has dropped over 50% due to a retraction in pandemic-related vaccine demand, following a significant price spike, presenting a potential buying opportunity for long-term investors.
- Patent Expiration Risks: The company faces risks from the expiration of patents on key drugs, with several set to expire by 2028, leading to concerns about declining sales and investor apprehension.
- Innovation and Investment Opportunities: Despite challenges, Pfizer is actively developing new drugs, including vaccines and oncology treatments, with plans for up to 20 pivotal studies in 2026, indicating its long-term investment potential amidst industry dynamics.
See More
Fulcrum Therapeutics Abandons Sickle-Cell Drug Development Amid FDA Concerns
- Stock Plunge: Fulcrum Therapeutics' shares plummeted 50% in premarket trading on Tuesday, reflecting strong market reaction to the company's decision to abandon its experimental sickle-cell disease drug following FDA cancer risk concerns, leading to a significant loss of investor confidence.
- Drug Development Setback: The company aimed to use pociredir to increase fetal hemoglobin levels for treating sickle-cell disease, but the FDA indicated that all drugs targeting the PRC2 protein complex carry similar malignancy risks, compounding the challenges in drug development.
- Strategic Shift: Fulcrum announced it would explore strategic options, including a potential sale or merger, and has begun cost-cutting measures to preserve cash, with current cash and investments totaling $333.3 million, indicating the company's response strategy amid significant challenges.
- Clinical Trial Insights: Despite the FDA's safety concerns, Fulcrum emphasized that no new safety issues had emerged in clinical trials, and pociredir demonstrated increases in fetal hemoglobin, which could help alleviate disease severity in sickle-cell patients.
See More
Long-Term Investment Opportunities in Healthcare Stocks
- CVS Health Recovery: CVS Health has outperformed broader equities over the past 12 months, with a market cap of $116 billion, driven by improved financial results, and plans to enhance profitability by scaling back its Medicare Advantage segment, solidifying its competitive edge in the U.S. healthcare market.
- AbbVie's Growth Drivers: Despite facing pressure from declining Humira sales, AbbVie's new drugs Skyrizi and Rinvoq continue to exceed expectations, with a market cap of $376 billion, and it is not expected to face significant patent losses over the next decade, indicating strong long-term growth potential in the biopharmaceutical sector.
- Pfizer's Transformation: Pfizer's stock is down over 50% from its all-time highs, but new products like the Abrysvo vaccine are performing well, with a market cap of $146 billion, and it is expected to achieve significant clinical progress in the coming years through a robust pipeline, restoring market confidence.
- Attractive Dividend Yields: CVS, AbbVie, and Pfizer all offer dividend yields above the market average, with CVS at 3%, AbbVie at 3.2%, and Pfizer at 6.6%, making them ideal choices for long-term investors seeking income.
See More
Long-Term Investment Opportunities in Healthcare Stocks
- CVS Health Recovery: CVS Health has outperformed broader equities over the past 12 months due to strong financial results and an improved medium-term outlook, despite challenges in its Medicare Advantage segment, with expectations of boosting profitable growth by scaling back this business over the next five years.
- AbbVie's Growth Drivers: Despite declining sales of Humira due to biosimilar competition, AbbVie's new drugs, Skyrizi and Rinvoq, continue to exceed expectations, and with no significant patent losses expected over the next decade, revenue and earnings are projected to grow steadily.
- Pfizer's Potential: Pfizer's stock is down over 50% from its all-time highs, but its extensive pipeline is expected to yield significant clinical advancements in the coming years, particularly in oncology and chronic weight management, making its current 6.6% forward yield attractive for long-term investors.
- Defensive Nature of Healthcare: Despite regulatory pressures and an uncertain outlook, the healthcare sector's trend towards increased spending makes high-quality dividend stocks a preferred choice for long-term investors, especially against the backdrop of a global aging population.
See More
Investment Comparison: AbbVie vs. Pfizer
- AbbVie's Financial Performance: In FY 2025, AbbVie reported revenue of approximately $61.2 billion, an 8.6% increase year-over-year, with a net income of about $4.2 billion and a net margin of 6.9%, indicating successful integration of new products despite customer concentration risks.
- Pfizer's Market Position: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6% from the previous year, yet achieved a net income close to $7.8 billion with a net margin of 12.4%, demonstrating effective cost management amid patent expiration challenges.
- Risk Overview: AbbVie faces significant revenue concentration with 42% of its income reliant on two major products, contending with competition from biosimilars and pricing pressures, while Pfizer must navigate patent expirations and high R&D costs, highlighting their strategic differences.
- Valuation Comparison: AbbVie has a forward P/E ratio of 14.7x compared to Pfizer's 8.7x, indicating that Pfizer appears more attractive in terms of valuation, although AbbVie shows stronger growth prospects and business stability.
See More
Comparative Investment Analysis of AbbVie and Pfizer
- Revenue Growth Comparison: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.6% increase, showcasing its robust pipeline in immunology and oncology despite facing patent cliffs.
- Profit Performance: Pfizer generated nearly $62.6 billion in revenue during the same fiscal year, a slight decline of 1.6% from the previous year, yet net income was close to $7.8 billion, yielding a net margin of 12.4%, indicating effective cost management.
- Financial Health Status: AbbVie's debt-to-equity ratio stands at -21.1x, indicating total liabilities exceed shareholder equity, while Pfizer's ratio is approximately 0.8x, demonstrating stronger financial leverage and short-term solvency.
- Market Competition and Risks: AbbVie relies on two major products for 42% of its revenue, facing competition from biosimilars, while Pfizer must manage revenue declines due to multiple patent expirations, requiring investors to weigh each company's growth potential against stability.
See More
Pfizer Faces Challenges Yet Remains a Long-Term Investment Opportunity
- Long History: Founded in 1849, Pfizer has survived over a century in the highly competitive pharmaceutical industry, with a corporate ethos emphasizing resilience in adversity, which instills confidence in investors.
- Stock Price Decline: Pfizer's stock has dropped over 50% due to a retraction in pandemic-related vaccine demand, following a significant price spike, presenting a potential buying opportunity for long-term investors.
- Patent Expiration Risks: The company faces risks from the expiration of patents on key drugs, with several set to expire by 2028, leading to concerns about declining sales and investor apprehension.
- Innovation and Investment Opportunities: Despite challenges, Pfizer is actively developing new drugs, including vaccines and oncology treatments, with plans for up to 20 pivotal studies in 2026, indicating its long-term investment potential amidst industry dynamics.
See More
Fulcrum Therapeutics Abandons Sickle-Cell Drug Development Amid FDA Concerns
- Stock Plunge: Fulcrum Therapeutics' shares plummeted 50% in premarket trading on Tuesday, reflecting strong market reaction to the company's decision to abandon its experimental sickle-cell disease drug following FDA cancer risk concerns, leading to a significant loss of investor confidence.
- Drug Development Setback: The company aimed to use pociredir to increase fetal hemoglobin levels for treating sickle-cell disease, but the FDA indicated that all drugs targeting the PRC2 protein complex carry similar malignancy risks, compounding the challenges in drug development.
- Strategic Shift: Fulcrum announced it would explore strategic options, including a potential sale or merger, and has begun cost-cutting measures to preserve cash, with current cash and investments totaling $333.3 million, indicating the company's response strategy amid significant challenges.
- Clinical Trial Insights: Despite the FDA's safety concerns, Fulcrum emphasized that no new safety issues had emerged in clinical trials, and pociredir demonstrated increases in fetal hemoglobin, which could help alleviate disease severity in sickle-cell patients.
See More
Long-Term Investment Opportunities in Healthcare Stocks
- CVS Health Recovery: CVS Health has outperformed broader equities over the past 12 months, with a market cap of $116 billion, driven by improved financial results, and plans to enhance profitability by scaling back its Medicare Advantage segment, solidifying its competitive edge in the U.S. healthcare market.
- AbbVie's Growth Drivers: Despite facing pressure from declining Humira sales, AbbVie's new drugs Skyrizi and Rinvoq continue to exceed expectations, with a market cap of $376 billion, and it is not expected to face significant patent losses over the next decade, indicating strong long-term growth potential in the biopharmaceutical sector.
- Pfizer's Transformation: Pfizer's stock is down over 50% from its all-time highs, but new products like the Abrysvo vaccine are performing well, with a market cap of $146 billion, and it is expected to achieve significant clinical progress in the coming years through a robust pipeline, restoring market confidence.
- Attractive Dividend Yields: CVS, AbbVie, and Pfizer all offer dividend yields above the market average, with CVS at 3%, AbbVie at 3.2%, and Pfizer at 6.6%, making them ideal choices for long-term investors seeking income.
See More
Long-Term Investment Opportunities in Healthcare Stocks
- CVS Health Recovery: CVS Health has outperformed broader equities over the past 12 months due to strong financial results and an improved medium-term outlook, despite challenges in its Medicare Advantage segment, with expectations of boosting profitable growth by scaling back this business over the next five years.
- AbbVie's Growth Drivers: Despite declining sales of Humira due to biosimilar competition, AbbVie's new drugs, Skyrizi and Rinvoq, continue to exceed expectations, and with no significant patent losses expected over the next decade, revenue and earnings are projected to grow steadily.
- Pfizer's Potential: Pfizer's stock is down over 50% from its all-time highs, but its extensive pipeline is expected to yield significant clinical advancements in the coming years, particularly in oncology and chronic weight management, making its current 6.6% forward yield attractive for long-term investors.
- Defensive Nature of Healthcare: Despite regulatory pressures and an uncertain outlook, the healthcare sector's trend towards increased spending makes high-quality dividend stocks a preferred choice for long-term investors, especially against the backdrop of a global aging population.
See More
Investment Comparison: AbbVie vs. Pfizer
- AbbVie's Financial Performance: In FY 2025, AbbVie reported revenue of approximately $61.2 billion, an 8.6% increase year-over-year, with a net income of about $4.2 billion and a net margin of 6.9%, indicating successful integration of new products despite customer concentration risks.
- Pfizer's Market Position: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6% from the previous year, yet achieved a net income close to $7.8 billion with a net margin of 12.4%, demonstrating effective cost management amid patent expiration challenges.
- Risk Overview: AbbVie faces significant revenue concentration with 42% of its income reliant on two major products, contending with competition from biosimilars and pricing pressures, while Pfizer must navigate patent expirations and high R&D costs, highlighting their strategic differences.
- Valuation Comparison: AbbVie has a forward P/E ratio of 14.7x compared to Pfizer's 8.7x, indicating that Pfizer appears more attractive in terms of valuation, although AbbVie shows stronger growth prospects and business stability.
See More
Comparative Investment Analysis of AbbVie and Pfizer
- Revenue Growth Comparison: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.6% increase, showcasing its robust pipeline in immunology and oncology despite facing patent cliffs.
- Profit Performance: Pfizer generated nearly $62.6 billion in revenue during the same fiscal year, a slight decline of 1.6% from the previous year, yet net income was close to $7.8 billion, yielding a net margin of 12.4%, indicating effective cost management.
- Financial Health Status: AbbVie's debt-to-equity ratio stands at -21.1x, indicating total liabilities exceed shareholder equity, while Pfizer's ratio is approximately 0.8x, demonstrating stronger financial leverage and short-term solvency.
- Market Competition and Risks: AbbVie relies on two major products for 42% of its revenue, facing competition from biosimilars, while Pfizer must manage revenue declines due to multiple patent expirations, requiring investors to weigh each company's growth potential against stability.
See More
